説明
Multi-panel analysis results labeled (c) and (d) from the synbiotic IBS-D trial present additional symptom domain comparisons.
Figure 22
ChartSource Paper
The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant …Cite This Figure
![Figure 22: Multi-panel analysis results labeled (c) and (d) from the synbiotic IBS-D trial present additional symptom domain comparisons.]() > Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." *Nutrients*, 2020. PMID: [32635661](https://pubmed.ncbi.nlm.nih.gov/32635661/)
<figure> <img src="" alt="Multi-panel analysis results labeled (c) and (d) from the synbiotic IBS-D trial present additional symptom domain comparisons." /> <figcaption>Figure 22. Multi-panel analysis results labeled (c) and (d) from the synbiotic IBS-D trial present additional symptom domain comparisons.<br> Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32635661/">32635661</a></figcaption> </figure>
関連するエビデンス
B
Bifidobacterium longum : Irritable Bowel Syndrome (IBS)
B
グレード B · 4 件の研究
Galactooligosaccharides (GOS) : Irritable Bowel Syndrome (IBS)
B
グレード B · 3 件の研究
Lactobacillus acidophilus : Irritable Bowel Syndrome (IBS)
D
グレード B · 3 件の研究
Fructooligosaccharides (FOS) : Irritable Bowel Syndrome (IBS)
グレード D · 2 件の研究